On June 26, 2025, Edgewise Therapeutics, Inc. announced positive results for its sevasemten program aimed at treating Becker and Duchenne muscular dystrophies, showing significant disease stabilization and improvements in patient assessments over 18 months. A total of 99% (n=85) of eligible participants are enrolled in the ongoing trial, and data indicate a favorable safety profile as Edgewise prepares for further discussions with the FDA regarding the registration of sevasemten.